Cemiplimab for treating cutaneous squamous cell carcinoma (CDF review TA592)
Cemiplimab for treating cutaneous squamous cell carcinoma (CDF review TA592)
This report is a critique of the company’s submission (CS) to the NICE Cancer Drugs Fund (CDF) review of TA592 on the clinical effectiveness and cost effectiveness of cemiplimab for treating cutaneous squamous cell carcinoma.
National Institute for Health and Care Research
Kalita, Neelam
da42f168-a3cc-44c9-bafb-2801ff57914b
Woods, Lois
8149aa11-7664-4052-a18b-98f7bde83180
Lord, Joanne
fd3b2bf0-9403-466a-8184-9303bdc80a9a
Frampton, Geoff
26c6163c-3428-45b8-b8b9-92091ff6c69f
June 2022
Kalita, Neelam
da42f168-a3cc-44c9-bafb-2801ff57914b
Woods, Lois
8149aa11-7664-4052-a18b-98f7bde83180
Lord, Joanne
fd3b2bf0-9403-466a-8184-9303bdc80a9a
Frampton, Geoff
26c6163c-3428-45b8-b8b9-92091ff6c69f
Kalita, Neelam, Woods, Lois, Lord, Joanne and Frampton, Geoff
(2022)
Cemiplimab for treating cutaneous squamous cell carcinoma (CDF review TA592)
(Health Technology Assessment, 135279)
National Institute for Health and Care Research
87pp.
Record type:
Monograph
(Project Report)
Abstract
This report is a critique of the company’s submission (CS) to the NICE Cancer Drugs Fund (CDF) review of TA592 on the clinical effectiveness and cost effectiveness of cemiplimab for treating cutaneous squamous cell carcinoma.
Text
ERG report - cemiplimab
- Version of Record
Available under License Other.
More information
Published date: June 2022
Identifiers
Local EPrints ID: 471451
URI: http://eprints.soton.ac.uk/id/eprint/471451
PURE UUID: 882a0a9d-708e-4f89-9f04-428f6a5791d3
Catalogue record
Date deposited: 08 Nov 2022 18:32
Last modified: 28 Aug 2024 01:59
Export record
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics